Cargando…
Diabetic nephropathy: What does the future hold?
The consensus management of diabetic nephropathy (DN) in 2015 involves good control of glycaemia, dyslipidaemia and blood pressure (BP). Blockade of the renin–angiotensin–aldosterone system using angiotensin-converting enzyme inhibitors, angiotensin-2 receptor blockers or mineralocorticoid inhibitor...
Autores principales: | Montero, R. M., Covic, A., Gnudi, L., Goldsmith, D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705119/ https://www.ncbi.nlm.nih.gov/pubmed/26438328 http://dx.doi.org/10.1007/s11255-015-1121-y |
Ejemplares similares
-
Treatment of membranous nephropathy: Perspectives on current and future therapies
por: Shah, Monarch, et al.
Publicado: (2023) -
Thyromimetics: What does the future hold?
por: Unnikrishnan, A. G., et al.
Publicado: (2012) -
What does the future hold?
por: de Campos, Fernando Peixoto Ferraz
Publicado: (2012) -
Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
por: Jacquot, Laetitia, et al.
Publicado: (2023) -
An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy
por: Shaw, Dylan J, et al.
Publicado: (2023)